Raj Vuppalanchi1, Raghavender Gotur1, K Rajender Reddy2, Robert J Fontana3, Marwan Ghabril1, Andrzej S Kosinski4, Jiezhun Gu4, Jose Serrano5, Naga Chalasani6. 1. Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 2. Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan. 4. Duke Clinical Research Institute, Durham, North Carolina. 5. Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. 6. Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address: nchalasa@iu.edu.
Abstract
BACKGROUND & AIMS: It is not known whether specific characteristics of medication are associated with type of drug-induced liver injury (DILI) or outcome. We examined the relationships among select characteristics of medications and DILI phenotype and outcome. METHODS: We analyzed 383 cases of DILI caused by a single orally administered prescription agent from the DILI Network Prospective Study with causalities of definite, highly likely, or probable. Relationship of daily dosage (≥50 mg vs ≤49 mg), preponderance of hepatic metabolism (≥50% vs <50%), or Biopharmaceutics Drug Disposition Classification System (BDDCS) class (1-4, based on solubility and metabolism of the drug) were compared with clinical characteristics and outcomes. RESULTS: Compared with cases of DILI in the ≤49 mg/day group, those associated with daily dosages ≥50 mg had shorter latency (median, 38 days vs 56 days; P = .03) and a different biochemical pattern of liver injury (P = .04); no differences in recovery, severity, or outcome were observed. Patients with DILI caused by medications with or without preponderant hepatic metabolism did not differ in clinical characteristics or outcomes. Compared with other classes of BDDCS, DILI caused by BDDCS class 1 medications had significantly longer latency (P < .001) and greater proportion of hepatocellular injury (P = .001). However, peak liver biochemical values and patients' time to recovery, disease severity, and outcomes did not differ among the 4 BDDCS classes. CONCLUSIONS: Characteristics of medications (dosage, hepatic metabolism, and solubility) are associated with features of DILI such as latency and pattern of liver injury, but not with recovery, severity, or outcome.
BACKGROUND & AIMS: It is not known whether specific characteristics of medication are associated with type of drug-induced liver injury (DILI) or outcome. We examined the relationships among select characteristics of medications and DILI phenotype and outcome. METHODS: We analyzed 383 cases of DILI caused by a single orally administered prescription agent from the DILI Network Prospective Study with causalities of definite, highly likely, or probable. Relationship of daily dosage (≥50 mg vs ≤49 mg), preponderance of hepatic metabolism (≥50% vs <50%), or Biopharmaceutics Drug Disposition Classification System (BDDCS) class (1-4, based on solubility and metabolism of the drug) were compared with clinical characteristics and outcomes. RESULTS: Compared with cases of DILI in the ≤49 mg/day group, those associated with daily dosages ≥50 mg had shorter latency (median, 38 days vs 56 days; P = .03) and a different biochemical pattern of liver injury (P = .04); no differences in recovery, severity, or outcome were observed. Patients with DILI caused by medications with or without preponderant hepatic metabolism did not differ in clinical characteristics or outcomes. Compared with other classes of BDDCS, DILI caused by BDDCS class 1 medications had significantly longer latency (P < .001) and greater proportion of hepatocellular injury (P = .001). However, peak liver biochemical values and patients' time to recovery, disease severity, and outcomes did not differ among the 4 BDDCS classes. CONCLUSIONS: Characteristics of medications (dosage, hepatic metabolism, and solubility) are associated with features of DILI such as latency and pattern of liver injury, but not with recovery, severity, or outcome.
Authors: Leslie Z Benet; Gordon L Amidon; Dirk M Barends; Hans Lennernäs; James E Polli; Vinod P Shah; Salomon A Stavchansky; Lawrence X Yu Journal: Pharm Res Date: 2008-01-31 Impact factor: 4.200
Authors: Jason D Hughes; Julian Blagg; David A Price; Simon Bailey; Gary A Decrescenzo; Rajesh V Devraj; Edmund Ellsworth; Yvette M Fobian; Michael E Gibbs; Richard W Gilles; Nigel Greene; Enoch Huang; Teresa Krieger-Burke; Jens Loesel; Travis Wager; Larry Whiteley; Yao Zhang Journal: Bioorg Med Chem Lett Date: 2008-07-24 Impact factor: 2.823
Authors: Naga Chalasani; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Timothy Davern; Jose Serrano; Hongqiu Yang; James Rochon Journal: Gastroenterology Date: 2008-09-17 Impact factor: 22.682
Authors: Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon Journal: Drug Saf Date: 2009 Impact factor: 5.606
Authors: Ann K Daly; Peter T Donaldson; Pallav Bhatnagar; Yufeng Shen; Itsik Pe'er; Aris Floratos; Mark J Daly; David B Goldstein; Sally John; Matthew R Nelson; Julia Graham; B Kevin Park; John F Dillon; William Bernal; Heather J Cordell; Munir Pirmohamed; Guruprasad P Aithal; Christopher P Day Journal: Nat Genet Date: 2009-05-31 Impact factor: 38.330
Authors: Giuseppe Marrone; Francesco Galati; Marco Biolato; Cristopher Oddy; Sara De Carolis; Angelo Zoli; Antonio Grieco Journal: BMC Gastroenterol Date: 2021-08-06 Impact factor: 3.067